Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

RU58841 not working for hair loss after 10 months. Concerns about purity of experimental drugs.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

User experienced hair growth after 4 months using Minoxidil and dermastamp. Others suggest adding Finasteride or Dutasteride for long-term results and trying microneedling with Minoxidil.

A 24-year-old male is considering the "Big 4" treatments (Finasteride, Minoxidil, Ketoconazole shampoo, and Microneedling) or a hair transplant for hair loss. Most users recommend starting with Finasteride and Minoxidil to stabilize hair loss before considering a transplant.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.

The user has been using finasteride for two years without results and recently started a new routine involving derma stamping, retinol, and minoxidil, which seems to show progress. The user microneedles about half the week and uses L’Oréal night serum for retinol.

The relative strength of Pyrilutamide compared to RU58841 in terms of androgen receptor binding affinity. It has been noted that Pyrilutamide is 4x stronger than RU58841, with a higher binding affinity than DHT itself.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

The user is seeking help with using Ell-Cranell for hair loss treatment. They are unsure about the correct application method and dosage. They also inquire about combining microneedling with topical alfatradiol and question a study that referred to alfatradiol as a hair growth inhibitor in male mice.

The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

A user shared their 4-year hair loss journey, starting with finasteride and minoxidil, then adding dutasteride and oral minoxidil, which improved their hair. They are now considering RU58841 and a hair transplant in the future.

The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.

The user has been using 1.5mg finasteride daily for four months and added minoxidil with a dermaroller for one month but stopped due to eye floaters. There is some improvement in hair regrowth, and suggestions include continuing treatment, using ketoconazole shampoo, and considering other supplements like vitamin D, saw palmetto, and biotin.

The conversation discusses a user's 4-month progress using topical minoxidil and 1.5-month use of topical finasteride, along with almost weekly microneedling, for hair loss. Some responses indicate noticeable improvement and encourage continued use, while others suggest it's too early to judge effectiveness and mention the possibility of a hair transplant.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.

RU58841 had mixed results for hair regrowth, with some users experiencing no change and others noting regrowth but also side effects like libido issues and chest pain. Some users combined it with other treatments like finasteride and dutasteride, with varying effectiveness.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

A user recently started using nanoxidil 5% for hair loss, particularly on the hairline, and is seeking feedback or experiences from others. The conversation focuses on the effectiveness of nanoxidil.

The conversation discusses the use of RU58841 for hair loss, with concerns about its legality in Germany and potential legal consequences. Alternatives like finasteride and dutasteride are mentioned, with some users questioning the effectiveness and safety of RU58841.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

The conversation discusses hair loss treatments, specifically topical finasteride and minoxidil, with users debating the effectiveness and honesty of progress pictures. Some users claim significant regrowth, while others argue about the influence of lighting and angles on perceived results.

The conversation is about a user experiencing small hair regrowth after 4 weeks of using oral Minoxidil and Dutasteride, and considering a future FUE transplant. Some users express skepticism about the regrowth, while others share similar experiences or doubts about the effectiveness of the treatment.

The user has been using topical minoxidil and finasteride for nearly four months, along with derma rolling and Nizoral, and is seeing noticeable hair regrowth and thickening, especially around the temples and crown. They are considering continuing the treatment and possibly trying oral finasteride, but are cautious due to a history of depression.

The conversation discusses CRISPR-on & CRISPR-off as a potential cure for baldness, contrasting it with hair cloning and other treatments like Minoxidil, finasteride, and RU58841. It also mentions the potential of mRNA for gene expression control and the prioritization of gene editing for severe genetic conditions.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.